A5006978040- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Global Cancer Incidence and Screening
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare Systems and Reforms
- Cancer survivorship and care
- Lung Cancer Diagnosis and Treatment
- Nutrition and Health in Aging
- COVID-19 and healthcare impacts
- Neutropenia and Cancer Infections
- Frailty in Older Adults
- Healthcare Systems and Public Health
- Global Public Health Policies and Epidemiology
- Economic and Financial Impacts of Cancer
- Gastric Cancer Management and Outcomes
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Screening and Detection
- Multiple and Secondary Primary Cancers
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Lung Cancer Research Studies
- Ferroptosis and cancer prognosis
University Medical Center Groningen
2022-2025
University of Groningen
2021-2024
Instituto Nacional de Salud Pública
2021
The introduction of immune checkpoint inhibitors (ICIs) has modified treatment modalities for patients with lung cancer, offering new alternatives treatment. Despite improved survival benefits, ICIs may cause side effects impacting patients' quality life (QoL). We aim to study the changes in global QoL (gQoL) advanced-stage cancer up 18 months after between 2015 and 2021. A longitudinal cohort was conducted using Oncological Life Study: Living well as a survivor data-biobank from University...
Pretreatment biomarkers are needed to identify patients with non-small-cell lung cancer (NSCLC) likely have worse survival. This ensures that only a real chance of benefit receive immune checkpoint inhibitor (ICI) treatment. In this study, we examined the associations baseline nutritional and inflammatory overall survival in real-world cohort NSCLC who received ICIs.
Lung cancer is the leading cause of mortality globally, with a 5-year survival rate 10-20%. In recent years, immune checkpoint inhibitors (ICIs) have significantly improved overall (OS) in patients lung cancer. The approval nivolumab 2015 marked milestone non-small cell (NSCLC) treatment, to ongoing trials and approvals new ICI drugs that reshaped treatment strategies clinical outcomes for This study aims describe ICIs prescription trends NSCLC Netherlands their association survival. We...
Immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, have significantly improved the clinical outcomes of various malignancies. However, they also cause immune-related adverse events (irAEs) that can be challenging to predict, prevent treat. Although likely interact with health-related quality life (HRQoL), most existing evidence on this topic has come from trials eligibility criteria may not accurately reflect real-world settings. The QUALITOP...
To describe the burden of colorectal cancer (CRC) in Mexico and understand mortality patterns based on sex, geography, insurance status.Mortality data (1998-2018) from Instituto Nacional de Estadística y Geografía was obtained. We included colon (C18.0, C18.2-18.9) rectal ICD-10 codes (C19, C20), estimated age-standardized national, state-level health rates. average annual percent change using joinpoint regression.Between 1998 2018, observed women men rate increased annually by 1.3 2.7%,...
As Mexico’s government restructures the health system, a comprehensive assessment of Seguro Popular’s Fund for Protection against Catastrophic Expenses (FPGC) can help inform decision makers to improve breast cancer outcomes and system performance. This study aimed estimate treatment gap patients treated under FPGC assess changes in this between 2007 (when coverage started treatment) 2016. We used nationwide administrative claims database whose was financed by period (56,847 women), Global...
Abstract Introduction This study aims to describe immune checkpoint inhibitors’ (ICIs) prescription trends for Non-small cell lung cancer (NSCLC) in the Netherlands and their association with survival. We compared our results data from randomized controlled trials (RCTs). Methods analyzed ICIs relationship survival using national-level Cancer Registry (NCR) first-line treatments 2016–2020. Additionally, we performed a secondary analysis Oncological Life Study (OncoLifeS) any-line treatments....
From 2005 to 2019, the Mexican government financed cervical cancer treatment for individuals without social security insurance through
Abstract Purpose: Women in low-and-middle income countries face persistent barriers to cervical cancer treatment. To reduce financial treatment, 2005 Mexico implemented public financing for treatment women with Seguro Popular, a government insurance program individuals without social security. Methods: We estimated the gap each year of 11-year period following this policy change by comparing number cases financed Popular estimates incident among used nationwide administrative database...
Objectives: Pretreatment biomarkers are needed to identify non-small cell lung cancer (NSCLC) patients with poorer chances of survival, so that only those a real chance benefit selected for Immune Checkpoint Inhibitor (ICI) treatment. Therefore, this study examined the association individual and combined nutritional inflammatory at baseline overall survival in NSCLC treated ICIs.Materials Methods: A retrospective analysis on prospective cohort was conducted consecutive series 502...